Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Authors

Mitchell S. Cairo, New York Medical CollegeFollow
Qiuhu Shi, New York Medical CollegeFollow
Allen J. Dozor, New York Medical CollegeFollow
Deborah Friedman, New York Medical CollegeFollow
Chitti R. Moorthy, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Allyson M. Flower, New York Medical CollegeFollow
Yaya Chu, New York Medical CollegeFollow
Harshini Mahanti, New York Medical College
Liana Klejmont, New York Medical CollegeFollow
Shalini Shenoy

Document Type

Abstract

Publication Date

11-2018

Journal Title

Blood

Department

Pediatrics

Second Department

Medicine

Third Department

Health Behavior and Community Health

Comments

Please see the work itself for the complete list of authors.

Recommended Citation

Cairo, M. S., Shi, Q., Dozor, A. J., Friedman, D., Moorthy, C. R., Ayello, J., Flower, A. M., Chu, Y., Mahanti, H., Klejmont, L., & Shenoy, S. (2018). Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). Blood, 132 (Suppl. 1), 162. https://doi.org/10.1182/blood-2018-162